Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dihydroergotamine Mesylate

FDA-approved product (injectable, injection), marketed as Atzumi, Brekiya (Autoinjector), D.h.e. 45 and 3 more.

Registered studies
21
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dihydroergotamine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ergot alkaloids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dihydroergotamine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dihydroergotamine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

    NCT07665892 · start 2026-05-26

    Registered record
    Registry ID
    NCT07665892
    Conditions
    Safety in Asthma Patients
    Interventions
    ASY202; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-26
    Completion
    2027-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety in Asthma Patients
    InterventionASY202; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

    NCT07646613 · start 2026-05-19

    Registered record
    Registry ID
    NCT07646613
    Conditions
    Migraine
    Interventions
    ASY202; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-19
    Completion
    2027-03
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionASY202; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

    NCT07226362 · start 2025-06-09

    Registered record
    Registry ID
    NCT07226362
    Conditions
    Safety, and Tolerability
    Interventions
    DHE inhalation powder low dose administered via dry powder inhaler (DPI) device; DHE inhalation powder high dose administered via dry powder inhaler (DPI) device; DHE injected intravenously (1 mg); DHE 2 mg administered by nasal spray (Migranal®); Metoclopramide 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-06-09
    Completion
    2025-10-02
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety, and Tolerability
    InterventionDHE inhalation powder low dose administered via dry powder inhaler (DPI) device; DHE inhalation powder high dose administered via dry powder inhaler (DPI) device; DHE injected intravenously (1 mg); DHE 2 mg administered by nasal spray (Migranal®) +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

    NCT05351086 · start 2022-06-09

    Registered record
    Registry ID
    NCT05351086
    Conditions
    Healthy
    Interventions
    PUR3100; Dihydroergotamine (D.H.E 45); Matching Placebo for PUR3100; Matching Placebo for D.H.E 45
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-09
    Completion
    2022-09-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPUR3100; Dihydroergotamine (D.H.E 45); Matching Placebo for PUR3100; Matching Placebo for D.H.E 45
    PhasePhase 1
    Registry statusCompleted

  • A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

    NCT04940390 · start 2021-06-30

    Registered record
    Registry ID
    NCT04940390
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2022-10-26
    Enrolment
    1,591

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

    NCT05337254 · start 2021-03-05

    Registered record
    Registry ID
    NCT05337254
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine; Dihydroergotamine; Dihydroergotamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-05
    Completion
    2021-06-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine; Dihydroergotamine; Dihydroergotamine
    PhasePhase 1
    Registry statusCompleted

  • Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

    NCT02706015 · start 2020-10

    Registered record
    Registry ID
    NCT02706015
    Conditions
    Migraine Headache
    Interventions
    Cefaliv® & Placebo; Neosaldina® & Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-10
    Completion
    2021-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionCefaliv® & Placebo; Neosaldina® & Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

    NCT04406649 · start 2020-09-14

    Registered record
    Registry ID
    NCT04406649
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-14
    Completion
    2023-01-16
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine
    PhasePhase 3
    Registry statusCompleted

  • Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

    NCT02582996 · start 2020-04

    Registered record
    Registry ID
    NCT02582996
    Conditions
    Migraine
    Interventions
    Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.; Acetaminophen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2020-04
    Completion
    2021-06
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionAcetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.; Acetaminophen
    PhasePhase 3
    Registry statusSuspended

  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

    NCT03901482 · start 2019-06-24

    Registered record
    Registry ID
    NCT03901482
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-24
    Completion
    2020-08-13
    Enrolment
    1,201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine; Placebos
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

    NCT03874832 · start 2018-09-11

    Registered record
    Registry ID
    NCT03874832
    Conditions
    Migraine With Aura; Migraine Without Aura; Migraine
    Interventions
    Dihydroergotamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-11
    Completion
    2018-11-07
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura; Migraine
    InterventionDihydroergotamine
    PhasePhase 1
    Registry statusCompleted

  • Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

    NCT03557333 · start 2018-07-13

    Registered record
    Registry ID
    NCT03557333
    Conditions
    Migraine Headache
    Interventions
    INP104
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2020-03-17
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionINP104
    PhasePhase 3
    Registry statusCompleted

  • Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

    NCT03401346 · start 2017-10-19

    Registered record
    Registry ID
    NCT03401346
    Conditions
    Migraine Headache
    Interventions
    INP104; Dihydroergotamine Mesylate (DHE); Migranal Nasal Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-19
    Completion
    2017-12-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionINP104; Dihydroergotamine Mesylate (DHE); Migranal Nasal Spray
    PhasePhase 1
    Registry statusCompleted

  • Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

    NCT03885154 · start 2017-10-03

    Registered record
    Registry ID
    NCT03885154
    Conditions
    Migraine in Children
    Interventions
    Valproic Acid (VPA); Dihydroergotamine (DHE)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-10-03
    Completion
    2019-03-19
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine in Children
    InterventionValproic Acid (VPA); Dihydroergotamine (DHE)
    PhasePhase 2
    Registry statusTerminated

  • QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

    NCT01191723 · start 2010-08

    Registered record
    Registry ID
    NCT01191723
    Conditions
    Healthy
    Interventions
    MAP0004; Inhaler Placebo; Moxifloxacin; Placebo Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-09
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMAP0004; Inhaler Placebo; Moxifloxacin; Placebo Capsule
    PhasePhase 1
    Registry statusCompleted